Log in to search using one of your social media accounts:

 

RA Efficacy, Safety Similar After Infliximab-to-SB2 Switch RA Efficacy, Safety Similar After Infliximab-to-SB2 Switch
Patients with RA who switched from infliximab to the biosimilar SB2 had ACR20 responses, adverse events, and immunogenicity profiles at 78 weeks similar to those in patients who continued infliximab.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Long-term Studies Back Biologic-to-Biosimilar Switch Long-term Studies Back Biologic-to-Biosimilar Switch
Researchers in Europe compared clinical response, remission, and immunogenicity to determine whether switching between innovator infliximab and the CTP-13 biosimilar has any effect on outcomes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 1, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

IBD patients may stay healthier when doctors monitor medications before they lose efficacy
(Beth Israel Deaconess Medical Center) Proactive monitoring of blood levels of the therapeutic drug infliximab was associated with improved outcomes including lower risk of surgery and hospitalization. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 3, 2017 Category: International Medicine & Public Health Source Type: news

Pfizer Files Suit Over Remicade Contracts Pfizer Files Suit Over Remicade Contracts
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 21, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Surgery an Alternative to Infliximab for Some People With Crohn ’ s Disease Surgery an Alternative to Infliximab for Some People With Crohn ’ s Disease
Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 21, 2017 Category: Surgery Tags: General Surgery News Source Type: news

Pfizer files lawsuit against J & J ’s exclusionary contracts for Remicade
Pfizer has filed a lawsuit against Johnson& Johnson (J&J) in the US District Court for the Eastern District of Pennsylvania to ensure patients and providers have access to major, lower-cost biosimilar therapies. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 20, 2017 Category: Pharmaceuticals Source Type: news

Pfizer sues J&J, claims ‘anticompetitive practices’ over Remicade biosimilar
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 20, 2017 Category: Pharmaceuticals Source Type: news

Merck, Samsung Bioepis launch discounted U.S. Remicade alternative
NEW YORK/SEOUL (Reuters) - Merck& Co and South Korea's Samsung Bioepis Co Ltd said on Monday they have begun selling a less expensive alternative version of Johnson& Johnson's rheumatoid arthritis drug Remicade in the United States, a move that should accelerate price declines for the big-selling medicine. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Merck launches biosimilar version of J & J blockbuster Remicade
Merck and Co. Inc. on Monday became the second pharmaceutical company to launch a biosimilar version of Remicade, a drug that generates billions of dollars a year in sales for Johnson& Johnson. Renflexis, the Merck biosimilar product, was approved by the Food and Drug Administration on April 21 as a treatment for rheumatoid arthritis, Crohn's disease, ulcerative colitis and ankylosing spondylitis. It is the first medicine available in the United States under a global biosimilars develop ment and… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 24, 2017 Category: Health Management Authors: John George Source Type: news

Samsung Bioepis launches U.S. sales of Remicade biosmiliar
SEOUL (Reuters) - South Korea's Samsung Bioepis Co Ltd said it started U.S sales of its copy of Johnson& Johnson's rheumatoid arthritis drug Remicade on Monday - a move set to further undermine sales of the U.S. firm's top-selling drug. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Nonmedical Biosimilar Switch Results Surprise Investigators Nonmedical Biosimilar Switch Results Surprise Investigators
When the Danish government mandated a switch to the infliximab biosimilar, researchers had the perfect opportunity to study the effect on patients with rheumatologic inflammatory disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 30, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Pregnancy and the Pharmacokinetics of Anti-TNF Agents in IBD Pregnancy and the Pharmacokinetics of Anti-TNF Agents in IBD
This study found that infliximab and adalimumab present differing effects.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Infliximab Induction Levels Predict IBD Treatment Failure Infliximab Induction Levels Predict IBD Treatment Failure
Lower infliximab trough levels during induction are associated with an increased risk of treatment failure during maintenance in patients with inflammatory bowel disease (IBD), researchers report.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - June 8, 2017 Category: Surgery Tags: Gastroenterology News Source Type: news

CT-P13, a Biosimilar of Anti-TNF-a for IBD CT-P13, a Biosimilar of Anti-TNF-a for IBD
Can CT-P13, a biosimilar of infliximab, be used safely in patients with inflammatory bowel diseases--and with comparable efficacy?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 25, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

UK CMA accuses Merck of breaking competition law with discount scheme
The UK Competition and Markets Authority (CMA) has accused US pharmaceutical company Merck Sharp& Dohme (MSD) of operating an anti-competitive discount scheme for its medicine Remicade. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 23, 2017 Category: Pharmaceuticals Source Type: news

UK watchdog accuses Merck of restricting biosimilar competition
Britain’s Competition and Markets Authority accused Merck‘s (NYSE:MRK) European unit, Merck Sharp & Dohme, of conducting an unfair discount scheme that it said was designed to restrict competition from biosimilar copies of the company’s drug, Remicade. Remicade is an antibody drug used to treat rheumatoid arthritis, ulcerative colitis and Chron’s disease. It was the 1st antibody drug to face competition from copycat versions in the European markets. Biosimilar drugmakers, including South Korea’s Celltrion, have launched discounted products that are “similar” enough to Remicade ...
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Wall Street Beat Merck Source Type: news

UK competition watchdog accuses Merck of obstructing biosimilars
LONDON (Reuters) - Britain's competition watchdog on Tuesday accused Merck& Co of operating an anti-competitive discount scheme for its medicine Remicade, designed to restrict competition from so-called biosimilar copies of the drug. (Source: Reuters: Health)
Source: Reuters: Health - May 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Janssen Biotech goes to court to block launch of Remicade biosimilar
Jansen Biotech is not going to let a second biosimilar version of its blockbuster rheumatoid arthritis drug Remicade hit pharmacy shelves in the United States without a fight. The Horsham, Pa.-based subsidiary of Johnson& Johnson (NYSE: JNJ) has filed a patent infringement lawsuit with U.S. District Court in New Jersey to prevent Samsung Bioepis Co. Ltd. of South Korea from introducing Renflexis later this year. Biosimilar products are different from generic drugs, which are chemically identical… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 19, 2017 Category: American Health Authors: John George Source Type: news

Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy
SEOUL (Reuters) - A unit of healthcare conglomerate Johnson& Johnson filed a lawsuit to block a copy of its rheumatoid arthritis drug Remicade made by South Korea's Samsung Bioepis Co Ltd from being sold in the United States. (Source: Reuters: Health)
Source: Reuters: Health - May 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Inflammatory Arthritis Stable after Switch to Biosimilar Infliximab (CME/CE)
(MedPage Today) -- Disease activity similar 1 year after non-medical switching in Denmark (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - May 14, 2017 Category: Geriatrics Source Type: news

' Fears Allayed' by Latest Infliximab Biosimilar Evidence'Fears Allayed' by Latest Infliximab Biosimilar Evidence
The biosimilar is noninferior to the originator infliximab in patients with stable Crohn's disease, ulcerative colitis, and other inflammatory conditions, two studies demonstrate.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 9, 2017 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Infliximab Biosimilar: Getting Closer to Interchangeability (CME/CE)
(MedPage Today) -- New studies show no differences in patients who switch (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 9, 2017 Category: Dermatology Source Type: news

Renflexis (Infliximab-abda Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 4, 2017 Category: Drugs & Pharmacology Source Type: news

Biosimilars Take Center Stage at Digestive Disease Week Biosimilars Take Center Stage at Digestive Disease Week
New phase 3 data comparing the efficacy and safety of infliximab with its biosimilar will be among the major research findings presented at Digestive Disease Week.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 3, 2017 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Samsung Bioepis receives FDA approval for Renflexis across all eligible indications
Samsung Bioepis has received the US Food and Drug Administration (FDA) approval for its biosimilar referencing Remicade (infliximab), Renflexis (infliximab-abda), across all eligible indications. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 24, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Second Biosimilar to Remicade (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and Andr é Sofair, MD, MPH The FDA late last week OK'd the second … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 24, 2017 Category: Primary Care Source Type: news

FDA approves Samsung Bioepis' copy of J & J's Remicade: company
SEOUL (Reuters) - South Korea's Samsung Bioepis Co Ltd said on Saturday the U.S. Food and Drug Administration approved its copy of Johnson& Johnson's rheumatoid arthritis drug Remicade, the first drug developed by the Samsung Group unit approved in the United States. (Source: Reuters: Health)
Source: Reuters: Health - April 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves 2nd near-copy of Remicade for immune disorders
Federal regulators have approved another alternative version of Remicade, an expensive injected drug widely used for rheumatoid arthritis and other immune system disorders (Source: ABC News: Health)
Source: ABC News: Health - April 21, 2017 Category: Consumer Health News Tags: Health Source Type: news

FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade
April 21, 2017 -- FDA today approved Renflexis (infliximab-abda) for multiple indications. Renflexis is administered by intravenous infusion. This is the second FDA-approved biosimilar to U.S.-licensed Remicade. A biosimilar product is a biological... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 21, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Clears Second Remicade Biosimilar (Renflexis) FDA Clears Second Remicade Biosimilar (Renflexis)
The FDA approves infliximab-abda (Renflexis, Samsung Bioepis) for multiple indications.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - April 21, 2017 Category: Dermatology Tags: Rheumatology News Alert Source Type: news

Dental implants in a young patient on Remicade infusions for cervical spondylitis?
I have a 39 year old male patient for dental implants who presents with cervical spondylosis and gets an infusion of infliximab (Remicaide) every 6 weeks. (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - April 5, 2017 Category: Dentistry Authors: osseonews Tags: Clinical Cases Surgical Source Type: news

What Causes Uveitis?
Discussion Inflammation of the middle layer of the eye, or uvea, is termed uveitis. Uveitis can be divided into anterior, intermediate or posterior uveitis by involving the anterior (iris and ciliary body), intermediate (vitreous) or posterior (choroid and usually retina) compartments. Panuveitis involves all 3 compartments. Duration can also be used to classify uveitis. Acute is 6 weeks and> 3 months is chronic persistent uveitis. Episodic periods of inactivity and reactivity that last more than 3 months are called recurrent uveitis. A third way to characterize uveitis is if it is granulomatous or not. Uveitis increase...
Source: PediatricEducation.org - April 3, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Remicade for Rheumatoid Arthritis Treatment
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 27, 2017 Category: Journals (General) Source Type: news

AS: TNF Inhibitors Differ in Uveitis Risk (CME/CE)
(MedPage Today) -- Adalimumab and infliximab have lowest risk (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 18, 2017 Category: Geriatrics Source Type: news

Infliximab Biosimilar Safe and Effective for Inflammatory Bowel Disease Infliximab Biosimilar Safe and Effective for Inflammatory Bowel Disease
The infliximab biosimilar CT-P13 (Remsima) is safe and effective against inflammatory bowel disease (IBD), according to a systematic review and meta-analysis.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 14, 2017 Category: Surgery Tags: Gastroenterology News Source Type: news

Infliximab Use Not Tied to Malignancy in Pediatric IBD Infliximab Use Not Tied to Malignancy in Pediatric IBD
Immunosuppressive therapy with infliximab (Remicade, Janssen) for inflammatory bowel disease (IBD) in pediatric patients is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis (HLH), according to a Janssen study.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 7, 2017 Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news

Biosimilar of costly inflammatory bowel disease therapy found safe and effective
(Wiley) Treatment of Crohn's disease and ulcerative colitis has been greatly improved by the introduction of biologic therapies such as infliximab (which targets tumour necrosis factor alpha), but at considerable cost. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 3, 2017 Category: Global & Universal Source Type: news

Infliximab vs. Adalimumab in Crohn's Disease Infliximab vs. Adalimumab in Crohn's Disease
Do the anti-TNF agents infliximab and adalimumab have comparable response characteristics? Are concomitant immunomodulators necessary for optimal response?Alimentary Pharmacology & Therapeutics (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 28, 2017 Category: Allergy & Immunology Tags: Gastroenterology Journal Article Source Type: news

Remicade vs. Humira
Title: Remicade vs. HumiraCategory: MedicationsCreated: 2/27/2017 12:00:00 AMLast Editorial Review: 2/27/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - February 27, 2017 Category: Drugs & Pharmacology Source Type: news

Johnson & Johnson Announces Further Patent and Trademark Office Action Related to REMICADE ®
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 23, 2017 Category: Pharmaceuticals Source Type: news

ICU Medical closes $900m buyout of Pfizer ’ s Hospira infusion pump biz
ICU Medical (NSDQ:ICUI) this week closed its $900 million acquisition of the Hospira infusion pump business from Pfizer (NYSE:PFE), confirming last year’s rumors that the drug giant was looking to sell the business. The deal, which was scaled back from $1 billion last month, called for ICU Medical to offer 3.2 million new shares, or $419.3 million, and $275 million in cash, along with an additional possible $225 million in cash based on performance milestones through the end of 2019. The transaction will put Hospira’s infusion systems business, including IV pumps, solutio...
Source: Mass Device - February 8, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Hospital Care Mergers & Acquisitions Wall Street Beat Hospira Inc. ICU Medical Inc. Pfizer Source Type: news

Getting back into the swing of things: Jake ’s journey with Crohn’s disease
It was a cloudy, September day at the Country Club of Miami in South Florida. Jake Goodstat, a high school sophomore and varsity golf player, approached the ninth green. He walked up to his ball with putter in hand, took a deep breath and gently tapped the ball to make the putt. He says this was the hole where he cinched second place in the 2016 South Florida Junior Golf Tournament. “It was the greatest feeling in the world to know that I placed,” recalls Jake, a Florida teen who underwent surgery two months prior to treat his Crohn’s disease. “Before my surgery, I...
Source: Thrive, Children's Hospital Boston - January 26, 2017 Category: Pediatrics Authors: Maureen McCarthy Tags: Diseases & Conditions Our Patients’ Stories Athos Bousvaros Center for Inflammatory Bowel Disease (IBD) Crohn's disease Robert Shamberger Source Type: news

Similar Long-Term Ulcerative Colitis Outcomes With Cyclosporine or Infliximab Similar Long-Term Ulcerative Colitis Outcomes With Cyclosporine or Infliximab
Long-term outcomes of patients with steroid-refractory acute severe ulcerative colitis (UC) are similar whether treated with cyclosporine or infliximab, researchers from France report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 18, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Medicare to Cover Infliximab Biosimilar
(MedPage Today) -- Cost to system is 15% lower than original Remicade (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - January 6, 2017 Category: Geriatrics Source Type: news

Pfizer agrees to $100m haircut in Hospira infusion sale to ICU Medical
Pfizer (NYSE:PFE) has agreed to take a $100 million hit on its previously $1 billion sale of its Hospira infusion pump business to ICU Medical (NSDQ:ICUI), bringing in approximately $900 million. The revised deal calls for ICU Medical to offer 3.2 million new shares, or $419.3 million, and $275 million in cash, along with an additional possible $225 million in cash based on performance milestones through the end of 2019. That deal is capped at $900 million, according to an SEC filing, $100 million less than the previously agreed upon $1 billion deal. The transaction will put Hospira’s infusion systems busin...
Source: Mass Device - January 6, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Hospira Inc. ICU Medical Inc. Pfizer Inc. Source Type: news

A Rocky Start for Biosimilar Inflectra?
(MedPage Today) -- Infliximab biosimilar approved, but obstacles remain (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 27, 2016 Category: Primary Care Source Type: news

New Test Yields Rapid Infliximab Drug Concentrations New Test Yields Rapid Infliximab Drug Concentrations
A new test provides rapid infliximab drug concentrations that enable immediate dosing adjustments, researchers from Belgium report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 21, 2016 Category: Pathology Tags: Gastroenterology News Source Type: news

European Studies of Infliximab Biosimilar Reassuring European Studies of Infliximab Biosimilar Reassuring
The infliximab biosimilar met the predefined noninferiority margin in two European studies, which will likely spur uptake of the FDA-approved product in the United States, experts say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 17, 2016 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Two Studies Reveal Differences In Real-World Treatment Patterns In Rheumatoid Arthritis Patients Taking Remicade ® (Infliximab) Compared To Ct-P13 (Infliximab Biosimilar)
Studies Presented at the 2016 ACR/ARHP Annual Meeting Reveal Higher Discontinuation Rates in Patients Newly Beginning or Switching to Treatment with CT-P13 (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 15, 2016 Category: Pharmaceuticals Source Type: news

October's top stories: GSK shingles vaccine, Pfizer ’s Inflectra injection in US
GSK submitted a biologics licence application to the FDA for its candidate shingles vaccine Shingrix, Pfizer announced its introduction of Inflectra (infliximab-dyyb) for injection in the US and Teva agreed to sell Actavis Generics assets and operati … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 10, 2016 Category: Pharmaceuticals Source Type: news